Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results

[1]  A. Ekici,et al.  Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus , 2022, Nature Medicine.

[2]  B. Weinshenker,et al.  Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials , 2021, Nature Reviews Neurology.

[3]  Guy B. Williams,et al.  Microglial activation and blood–brain barrier permeability in cerebral small vessel disease , 2021, Brain : a journal of neurology.

[4]  S. Schuster,et al.  Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. , 2021, The New England journal of medicine.

[5]  L. Meng,et al.  A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. , 2021, Blood.

[6]  Jacqueline Palace,et al.  New therapies for neuromyelitis optica spectrum disorder , 2020, The Lancet Neurology.

[7]  H. Hartung,et al.  Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[8]  F. Paul,et al.  Neuromyelitis optica , 2020, Nature Reviews Disease Primers.

[9]  J. Kochenderfer,et al.  CAR T cell therapies for patients with multiple myeloma , 2020, Nature Reviews Clinical Oncology.

[10]  E. Radaelli,et al.  Antigen-specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris. , 2020, The Journal of clinical investigation.

[11]  Jia Gu,et al.  Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR. , 2020, The Journal of molecular diagnostics : JMD.

[12]  Jacqueline Palace,et al.  Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[13]  Gary R Cutter,et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial , 2019, The Lancet.

[14]  Mhs,et al.  Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder , 2019 .

[15]  S. Jagannath,et al.  Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma , 2019, The New England journal of medicine.

[16]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  B. Lei,et al.  A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma , 2018, Journal of Hematology & Oncology.

[18]  Jianfeng Zhou,et al.  Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma , 2018, Journal of Hematology & Oncology.

[19]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[20]  Michael L. Wang,et al.  T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Syed Abbas Ali,et al.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.

[22]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[23]  K. Fujihara,et al.  Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica , 2015, Journal of Neuroimmunology.

[24]  I. Caruana,et al.  From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. , 2014, Seminars in oncology.

[25]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[26]  Y. Itoyama,et al.  Pain in neuromyelitis optica and its effect on quality of life , 2011, Neurology.

[27]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[28]  Y. Itoyama,et al.  Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. , 2006, The Tohoku journal of experimental medicine.

[29]  A. Rajasekaran,et al.  Biological impediments to monoclonal antibody-based cancer immunotherapy. , 2004, Molecular cancer therapeutics.